Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer

Cell Reports

Volumn 8, Issue 5, 2014, Pages 1339-1346

  Wang, Zhu A ^a,c   Toivanen, Roxanne ^a   Bergren, Sarah K ^a   Chambon, Pierre ^b   Shen, Michael M ^a  

^a Departments of Medicine Genetics and Development Urology and Systems Biology Columbia Stem Cell Initiative Herbert Irving Comprehensive Cancer Center Columbia University College of Physicians and Surgeons ^*  (United States)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; DEATH RECEPTOR 3; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, MOUSE; PTEN PROTEIN, MOUSE; TNFRSF25 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; EPITHELIUM CELL; HORMONAL CARCINOGENESIS; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PROSTATE CANCER; PROSTATE LUMINAL CELL; ANIMAL; C57BL MOUSE; CANCER STEM CELL; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

MUS;

ANIMALS; CELL LINEAGE; EPITHELIAL CELLS; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; TRANSCRIPTION FACTORS;

EID: 84922550917     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.002     Document Type: Article

References (40)

1. Blackwood J.K., Williamson S.C., Greaves L.C., Wilson L., Rigas A.C., Sandher R., Pickard R.S., Robson C.N., Turnbull D.M., Taylor R.W., Heer R. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J.Pathol. 2011, 225:181-188.
2. Blanpain C. Tracing the cellular origin of cancer. Nat. Cell Biol. 2013, 15:126-134.
3. Bosland M.C., Ford H., Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995, 16:1311-1317.
4. Choi N., Zhang B., Zhang L., Ittmann M., Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012, 21:253-265.
5. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
6. Gaisa N.T., Graham T.A., McDonald S.A., Poulsom R., Heidenreich A., Jakse G., Knuechel R., Wright N.A. Clonal architecture of human prostatic epithelium in benign and malignant conditions. J.Pathol. 2011, 225:172-180.
7. Goldstein A.S., Witte O.N. Does the microenvironment influence the cell types of origin for prostate cancer?. Genes Dev. 2013, 27:1539-1544.
8. Goldstein A.S., Lawson D.A., Cheng D., Sun W., Garraway I.P., Witte O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. USA 2008, 105:20882-20887.
9. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
10. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 1995, 92:3439-3443.
11. Gurel B., Iwata T., Koh C.M., Jenkins R.B., Lan F., Van Dang C., Hicks J.L., Morgan J., Cornish T.C., Sutcliffe S., et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008, 21:1156-1167.
12. Irshad S., Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev. 2013, 32:109-122.
13. Ittmann M., Huang J., Radaelli E., Martin P., Signoretti S., Sullivan R., Simons B.W., Ward J.M., Robinson B.D., Chu G.C., et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013, 73:2718-2736.
14. Jäämaa S., Af Hällström T.M., Sankila A., Rantanen V., Koistinen H., Stenman U.H., Zhang Z., Yang Z., De Marzo A.M., Taari K., et al. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res. 2010, 70:8630-8641.
15. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 2002, 99:2884-2889.
16. Kwon O.J., Zhang L., Ittmann M.M., Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc. Natl. Acad. Sci. USA 2014, 111:E592-E600.
17. Lawson D.A., Xin L., Lukacs R.U., Cheng D., Witte O.N. Isolation and functional characterization of murine prostate stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:181-186.
18. Lawson D.A., Zong Y., Memarzadeh S., Xin L., Huang J., Witte O.N. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl. Acad. Sci. USA 2010, 107:2610-2615.
19. Liu C., Zong H. Developmental origins of brain tumors. Curr. Opin. Neurobiol. 2012, 22:844-849.
20. Liu C., Sage J.C., Miller M.R., Verhaak R.G., Hippenmeyer S., Vogel H., Foreman O., Bronson R.T., Nishiyama A., Luo L., Zong H. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011, 146:209-221.
21. Lu T.L., Huang Y.F., You L.R., Chao N.C., Su F.Y., Chang J.L., Chen C.M. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am. J. Pathol. 2013, 182:975-991.
22. Meeker A.K., Hicks J.L., Platz E.A., March G.E., Bennett C.J., Delannoy M.J., De Marzo A.M. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002, 62:6405-6409.
23. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977, 37:1929-1933.
24. Ousset M., Van Keymeulen A., Bouvencourt G., Sharma N., Achouri Y., Simons B.D., Blanpain C. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat. Cell Biol. 2012, 14:1131-1138.
25. Ratnacaram C.K., Teletin M., Jiang M., Meng X., Chambon P., Metzger D. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 2008, 105:2521-2526.
26. Ricke W.A., McPherson S.J., Bianco J.J., Cunha G.R., Wang Y., Risbridger G.P. Prostatic hormonal carcinogenesis is mediated by insitu estrogen production and estrogen receptor alpha signaling. FASEB J. 2008, 22:1512-1520.
27. Rock J.R., Onaitis M.W., Rawlins E.L., Lu Y., Clark C.P., Xue Y., Randell S.H., Hogan B.L. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. USA 2009, 106:12771-12775.
28. Shappell S.B., Thomas G.V., Roberts R.L., Herbert R., Ittmann M.M., Rubin M.A., Humphrey P.A., Sundberg J.P., Rozengurt N., Barrios R., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004, 64:2270-2305.
29. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
30. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001, 1:4.
31. Stoyanova T., Cooper A.R., Drake J.M., Liu X., Armstrong A.J., Pienta K.J., Zhang H., Kohn D.B., Huang J., Witte O.N., Goldstein A.S. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc. Natl. Acad. Sci. USA 2013, 110:20111-20116.
32. Taylor R.A., Toivanen R., Frydenberg M., Pedersen J., Harewood L., Collins A.T., Maitland N.J., Risbridger G.P. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 2012, 30:1087-1096. Australian Prostate Cancer Bioresource.
33. Van Keymeulen A., Rocha A.S., Ousset M., Beck B., Bouvencourt G., Rock J., Sharma N., Dekoninck S., Blanpain C. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011, 479:189-193.
34. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23:2563-2577.
35. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
36. Wang Z.A., Shen M.M. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011, 30:1261-1271.
37. Wang Y., Hayward S.W., Donjacour A.A., Young P., Jacks T., Sage J., Dahiya R., Cardiff R.D., Day M.L., Cunha G.R. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 2000, 60:6008-6017.
38. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.-P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
39. Wang Z.A., Mitrofanova A., Bergren S.K., Abate-Shen C., Cardiff R.D., Califano A., Shen M.M. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat. Cell Biol. 2013, 15:274-283.
40. Xin L. Cells of origin for cancer: an updated view from prostate cancer. Oncogene 2013, 32:3655-3663.